| __timestamp | Dynavax Technologies Corporation | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84580000 | 293000 |
| Thursday, January 1, 2015 | 86943000 | 1002000 |
| Friday, January 1, 2016 | 84493000 | 888000 |
| Sunday, January 1, 2017 | 64988000 | 19623000 |
| Monday, January 1, 2018 | 74951000 | 30421000 |
| Tuesday, January 1, 2019 | 62331000 | 34794000 |
| Wednesday, January 1, 2020 | 28607000 | 28304000 |
| Friday, January 1, 2021 | 32228000 | 56886000 |
| Saturday, January 1, 2022 | 46600000 | 100894000 |
| Sunday, January 1, 2023 | 54886000 | 159765000 |
Data in motion
In the ever-evolving biotech landscape, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Dynavax Technologies Corporation and Viridian Therapeutics, Inc. have shown distinct approaches to R&D investment.
From 2014 to 2023, Dynavax's R&D expenses fluctuated, peaking in 2015 with a 14% increase from the previous year, before experiencing a significant dip in 2020. In contrast, Viridian's R&D spending skyrocketed, especially from 2020 onwards, culminating in a staggering 460% increase by 2023 compared to 2014. This surge reflects Viridian's aggressive push towards innovation and market expansion.
These trends highlight the strategic priorities of each company, with Dynavax maintaining steady investment and Viridian ramping up efforts to capture new opportunities. As the biotech sector continues to grow, understanding these spending patterns offers valuable insights into each company's future trajectory.
R&D Insights: How Amgen Inc. and Viridian Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Sanofi vs Viridian Therapeutics, Inc.
R&D Spending Showdown: Gilead Sciences, Inc. vs Viridian Therapeutics, Inc.
Genmab A/S or Dynavax Technologies Corporation: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Intra-Cellular Therapies, Inc. and Dynavax Technologies Corporation
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Viridian Therapeutics, Inc.
R&D Insights: How Ascendis Pharma A/S and Viridian Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Jazz Pharmaceuticals plc and Dynavax Technologies Corporation
R&D Spending Showdown: Grifols, S.A. vs Dynavax Technologies Corporation
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Viridian Therapeutics, Inc.
Research and Development Investment: CRISPR Therapeutics AG vs Viridian Therapeutics, Inc.
R&D Spending Showdown: MorphoSys AG vs Dynavax Technologies Corporation